Key terms
About GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GERN news
Mar 19
9:18am ET
Geron prices $150M offering of common stock and warrants at $3.00 per share
Mar 19
2:40am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Mar 18
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 18
8:45am ET
Largest borrow rate increases among liquid names
Mar 15
9:25am ET
Geron price target raised to $5 from $4 at Needham
Mar 14
3:56pm ET
Geron reports FDA advisors vote in favor of benefit/risk of imetelstat
Mar 12
2:15pm ET
Optimistic Buy Rating on Geron Corp Amid FDA Scrutiny of Imetelstat
Mar 12
12:42pm ET
B. Riley sees closely contested vote after ‘hair-raising’ Geron briefing docs
Mar 12
10:47am ET
FDA says ‘not clear’ magnitude, durability of RBC-TI outweighs Geron drug risks
Mar 12
5:50am ET
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), ACELYRIN, INC. (SLRN) and Geron (GERN)
Mar 11
1:25pm ET
Needham biotechnology analyst to hold an analyst/industry conference call
Mar 11
9:10am ET
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)
Mar 08
3:36pm ET
FDA Oncologic Drugs Advisory Committee holds virtual meeting
Mar 04
1:35pm ET
Needham biotechnology analyst to hold an analyst/industry conference call
Feb 29
8:19am ET
Stifel Nicolaus Sticks to Its Buy Rating for Geron (GERN)
Feb 29
6:51am ET
Geron price target lowered to $4.50 from $5 at Baird
Feb 28
8:15pm ET
Buy Rating on Geron Corp. Anchored by Imetelstat’s FDA Approval Outlook and Favorable Safety Profile
Feb 28
11:55am ET
Buy Rating Affirmed for Geron on Strong Cash Position and Positive Clinical Study Projections
Feb 28
7:23am ET
Geron sees FY24 total operating expenses $270M- $280M
Feb 28
7:21am ET
Geron reports Q EPS (9c), consensus (10c)
Feb 14
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Feb 12
9:40am ET
Unusually active option classes on open February 12th
No recent news articles are available for GERN
No recent press releases are available for GERN
GERN Financials
Key terms
Ad Feedback
GERN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GERN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
